Abbott India Limited (IN:ABBOTINDIA)
:ABBOTINDIA
Want to see IN:ABBOTINDIA full AI Analyst Report?
Top Page
Abbott India Limited
(ABBOTINDIA)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹27,593.00
▼(-1.81% Downside)
Action:ReiteratedDate:10/25/25
Abbott India Limited's strong financial performance is the primary driver of its overall stock score, supported by robust profitability and a solid balance sheet. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.
Positive Factors
Balance Sheet Strength
Abbott India's low leverage and strong equity ratio indicate durable financial resilience. This reduces refinancing and interest-rate risks, preserves borrowing capacity for capex or M&A, and supports steady shareholder returns. A robust balance sheet underpins strategic flexibility over months to years.
Negative Factors
Moderate Revenue Growth
Mid-single-digit revenue growth suggests limited top-line momentum relative to high-growth healthcare peers. Over 2-6 months this can constrain scalability and reinvestment capacity; in a competitive branded-generics market, stronger growth is typically required to expand margins and justify higher reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Abbott India's low leverage and strong equity ratio indicate durable financial resilience. This reduces refinancing and interest-rate risks, preserves borrowing capacity for capex or M&A, and supports steady shareholder returns. A robust balance sheet underpins strategic flexibility over months to years.
Read all positive factors
Abbott India Limited (ABBOTINDIA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹540.39B
Dividend Yield1.68%
Average Volume (3M)628.00
Price to Earnings (P/E)41.0
Beta (1Y)0.54
Revenue Growth9.31%
EPS Growth14.21%
CountryIN
Employees3,814
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)710.09
Shares Outstanding21,249,302
10 Day Avg. Volume806
30 Day Avg. Volume628
Financial Highlights & Ratios
PEG Ratio2.57
Price to Book (P/B)15.22
Price to Sales (P/S)10.06
P/FCF Ratio67.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹32,150.00Price Target Upside14.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)817.25
Revenue Forecast (FY)₹74.94B
Abbott India Limited Business Overview & Revenue Model
Company Description
Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vita...
How the Company Makes Money
Abbott India primarily makes money by selling pharmaceutical and healthcare products in India. Its core revenue stream is the sale of branded prescription medicines (often referred to as branded generics and established brands) across key therapy ...
Abbott India Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.12B | 64.07B | 58.47B | 53.47B | 49.10B | 43.08B |
| Gross Profit | 30.70B | 28.96B | 26.15B | 23.63B | 22.43B | 19.10B |
| EBITDA | 21.03B | 19.70B | 17.01B | 13.60B | 11.65B | 10.01B |
| Net Income | 15.09B | 14.14B | 12.01B | 9.49B | 7.99B | 6.91B |
Balance Sheet | ||||||
| Total Assets | 56.94B | 59.17B | 51.93B | 45.56B | 42.24B | 38.40B |
| Cash, Cash Equivalents and Short-Term Investments | 23.42B | 31.13B | 21.18B | 19.22B | 27.35B | 23.98B |
| Total Debt | 1.82B | 1.97B | 832.30M | 1.13B | 1.52B | 1.53B |
| Total Liabilities | 16.84B | 16.84B | 14.95B | 13.67B | 14.04B | 12.38B |
| Stockholders Equity | 40.11B | 42.33B | 36.99B | 31.89B | 28.20B | 26.02B |
Cash Flow | ||||||
| Free Cash Flow | 5.05B | 9.59B | 11.64B | 8.59B | 9.04B | 7.03B |
| Operating Cash Flow | 5.22B | 10.12B | 12.13B | 8.93B | 9.48B | 7.27B |
| Investing Cash Flow | 5.48B | 1.82B | -4.16B | -1.48B | -3.96B | -718.20M |
| Financing Cash Flow | -10.40B | -9.25B | -7.45B | -6.39B | -6.37B | -5.82B |
Abbott India Limited Technical Analysis
Negative
28101.15
Price Trends
26555.35
Negative
27501.68
Negative
29583.62
Negative
Market Momentum
-258.43
Negative
43.71
Neutral
49.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 28101.15 is above the 20-day moving average (MA) of 26092.72, above the 50-day MA of 26555.35, and below the 200-day MA of 29583.62, indicating a bearish trend. The MACD of -258.43 indicates Negative momentum. The RSI at 43.71 is Neutral, neither overbought nor oversold. The STOCH value of 49.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.
Abbott India Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹807.05B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
72 Outperform | ₹1.05T | 20.49 | ― | 0.57% | 18.86% | 61.69% | |
72 Outperform | ₹897.21B | 22.07 | ― | 1.19% | 17.27% | 8.99% | |
67 Neutral | ₹540.39B | 41.01 | ― | 1.68% | 9.31% | 14.21% | |
63 Neutral | ₹582.23B | 91.56 | ― | 0.12% | 13.99% | -27.80% | |
63 Neutral | ₹395.66B | 35.44 | ― | 2.16% | 2.59% | 18.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ABBOTINDIA
Abbott India Limited
25,430.90
-4,921.74
-16.22%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,389.55
151.50
12.24%
IN:BIOCON
Biocon Limited
359.55
24.15
7.20%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,335.60
-521.07
-18.24%
IN:LUPIN
Lupin Limited
2,303.70
229.29
11.05%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
891.65
9.61
1.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.